Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer’s Disease

Molecular Neurobiology

Volumn 53, Issue 4, 2016, Pages 2489-2497

  Jiang, Teng ^a   Zhang, Ying Dong ^a   Zhou, Jun Shan ^a   Zhu, Xi Chen ^b   Tian, You Yong ^a   Zhao, Hong Dong ^a   Lu, Huan ^b   Gao, Qing ^a   Tan, Lan ^b   Yu, Jin Tai ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer s disease; Angiotensin (1 7); Hyperphosphorylation; P301S mice; SAMP8; Tau

Indexed keywords

ANGIOTENSIN[1-7]; TAU PROTEIN; ANGIOTENSIN I; ANGIOTENSIN I (1-7); PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HIPPOCAMPUS; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; TAU HYPERPHOSPHORYLATION; TAUOPATHY; ANIMAL; BRAIN; C57BL MOUSE; DISEASE MODEL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANGIOTENSIN I; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; MALE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84930536005     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9260-9     Document Type: Article

References (44)

1. Jiang T, Yu JT, Tian Y, Tan L (2013) Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res 10(8):852–867
2. Jiang T, Yu JT, Tan L (2012) Novel disease-modifying therapies for Alzheimer’s disease. J Alzheimers Dis 31(3):475–492. doi:10.3233/JAD-2012-120640
3. Wright JW, Harding JW (2011) Brain renin-angiotensin—a new look at an old system. Prog Neurobiol 95(1):49–67. doi:10.1016/j.pneurobio.2011.07.001
4. Wright JW, Harding JW (2013) The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers Arch-Eur J Physiol 465(1):133–151. doi:10.1007/s00424-012-1102-2
5. Wright JW, Harding JW (2010) The brain RAS and Alzheimer’s disease. Exp Neurol 223(2):326–333. doi:10.1016/j.expneurol.2009.09.012
6. Wright JW, Kawas LH, Harding JW (2013) A role for the brain RAS in Alzheimer’s and Parkinson’s diseases. Front Endocrinol 4:158. doi:10.3389/fendo.2013.00158
7. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S et al (2009) Angiotensin-converting enzyme levels and activity in Alzheimer’s disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res 1(2):163–177
8. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol 34(2):181–193. doi:10.1111/j.1365-2990.2007.00885.x
9. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, Tong Q (2011) Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats. PLoS ONE 6(1):e16037. doi:10.1371/journal.pone.0016037
10. Tian M, Zhu D, Xie W, Shi J (2012) Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett 586(20):3737–3745. doi:10.1016/j.febslet.2012.09.004
11. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, Sueta D, Koibuchi N et al (2011) Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J Off Publ Fed Am Soc Exp Biol 25(9):2911–2920. doi:10.1096/fj.11-182873
12. Ongali B, Nicolakakis N, Tong XK, Aboulkassim T, Papadopoulos P, Rosa-Neto P, Lecrux C, Imboden H et al (2014) Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol Dis 68C:126–136. doi:10.1016/j.nbd.2014.04.018
13. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B (2010) Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340:b5465. doi:10.1136/bmj.b5465
14. Qiu WQ, Mwamburi M, Besser LM, Zhu H, Li H, Wallack M, Phillips L, Qiao L et al (2013) Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer’s disease in the absence of apolipoprotein E4 allele. J Alzheimers Dis 37(2):421–428. doi:10.3233/JAD-130716
15. Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, Fitzpatrick AL, Fried LP et al (2013) Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology 81(10):896–903. doi:10.1212/WNL.0b013e3182a35228
16. Xu P, Sriramula S, Lazartigues E (2011) ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good. Am J Physiol Regul Integr Comp Physiol 300(4):R804–R817. doi:10.1152/ajpregu.00222.2010
17. Jiang T, Gao L, Lu J, Zhang YD (2013) ACE2-Ang-(1-7)-Mas axis in brain: a potential target for prevention and treatment of ischemic stroke. Curr Neuropharmacol 11(2):209–217. doi:10.2174/1570159X11311020007
18. Hellner K, Walther T, Schubert M, Albrecht D (2005) Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci 29(3):427–435. doi:10.1016/j.mcn.2005.03.012
19. Lazaroni TL, Raslan AC, Fontes WR, de Oliveira ML, Bader M, Alenina N, Moraes MF, Dos Santos RA et al (2012) Angiotensin-(1-7)/Mas axis integrity is required for the expression of object recognition memory. Neurobiol Learn Mem 97(1):113–123. doi:10.1016/j.nlm.2011.10.003
20. Jiang T, Gao L, Shi J, Lu J, Wang Y, Zhang Y (2013) Angiotensin-(1-7) modulates renin-angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol Res Off J Ital Pharmacol Soc 67(1):84–93. doi:10.1016/j.phrs.2012.10.014
21. Jiang T, Gao L, Zhu XC, Yu JT, Shi JQ, Tan MS, Lu J, Tan L et al (2013) Angiotensin-(1-7) inhibits autophagy in the brain of spontaneously hypertensive rats. Pharmacol Res Off J Ital Pharmacol Soc 71:61–68. doi:10.1016/j.phrs.2013.03.001
22. Xie W, Zhu D, Ji L, Tian M, Xu C, Shi J (2014) Angiotensin-(1-7) improves cognitive function in rats with chronic cerebral hypoperfusion. Brain Res. doi:10.1016/j.brainres.2014.05.019
23. Wang H, Lian K, Han B, Wang Y, Kuo SH, Geng Y, Qiang J, Sun M et al (2014) Age-related alterations in the metabolic profile in the hippocampus of the senescence-accelerated mouse prone 8: a spontaneous Alzheimer’s disease mouse model. J Alzheimers Dis 39(4):841–848. doi:10.3233/JAD-131463
24. Cheng XR, Cui XL, Zheng Y, Zhang GR, Li P, Huang H, Zhao YY, Bo XC et al (2013) Nodes and biological processes identified on the basis of network analysis in the brain of the senescence accelerated mice as an Alzheimer’s disease animal model. Front Aging Neurosci 5:65. doi:10.3389/fnagi.2013.00065
25. Morley JE, Armbrecht HJ, Farr SA, Kumar VB (2012) The senescence accelerated mouse (SAMP8) as a model for oxidative stress and Alzheimer’s disease. Biochim Biophys Acta 1822(5):650–656. doi:10.1016/j.bbadis.2011.11.015
26. Canudas AM, Gutierrez-Cuesta J, Rodriguez MI, Acuna-Castroviejo D, Sureda FX, Camins A, Pallas M (2005) Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech Ageing Dev 126(12):1300–1304. doi:10.1016/j.mad.2005.07.008
27. Ozcelik S, Fraser G, Castets P, Schaeffer V, Skachokova Z, Breu K, Clavaguera F, Sinnreich M et al (2013) Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice. PLoS ONE 8(5):e62459. doi:10.1371/journal.pone.0062459
28. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL (2010) Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160(7):1573–1576. doi:10.1111/j.1476-5381.2010.00873.x
29. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010) Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160(7):1577–1579. doi:10.1111/j.1476-5381.2010.00872.x
30. Hooijmans CR, de Vries R, Leenaars M, Curfs J, Ritskes-Hoitinga M (2011) Improving planning, design, reporting and scientific quality of animal experiments by using the Gold Standard Publication Checklist, in addition to the ARRIVE guidelines. Br J Pharmacol 162(6):1259–1260. doi:10.1111/j.1476-5381.2010.01128.x
31. Liu S, Liu J, Miura Y, Tanabe C, Maeda T, Terayama Y, Turner AJ, Zou K et al (2014) Conversion of Abeta43 to Abeta40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme. J Neurosci Res. doi:10.1002/jnr.23404
32. Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L, Wang HF, Lu J et al (2014) Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas/eNOS-dependent pathway. Br J Pharmacol 171(18):4222–4232. doi:10.1111/bph.12770
33. Jiang T, Yu JT, Zhu XC, Tan MS, Wang HF, Cao L, Zhang QQ, Shi JQ et al (2014) Temsirolimus promotes autophagic clearance of amyloid-beta and provides protective effects in cellular and animal models of Alzheimer’s disease. Pharmacol Res Off J Ital Pharmacol Soc 81:54–63. doi:10.1016/j.phrs.2014.02.008
34. Jiang T, Yu JT, Zhu XC, Tan MS, Gu LZ, Zhang YD, Tan L (2014) Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35(6):1243–1251. doi:10.1016/j.neurobiolaging.2013.11.026
35. Jiang T, Yu JT, Zhu XC, Wang HF, Tan MS, Cao L, Zhang QQ, Gao L et al (2014) Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy. Br J Pharmacol 171(13):3146–3157. doi:10.1111/bph.12655
36. Jiang T, Yu JT, Zhu XC, Zhang QQ, Tan MS, Cao L, Wang HF, Shi JQ et al (2014) Ischemic preconditioning provides neuroprotection by induction of AMP-activated protein kinase-dependent autophagy in a rat model of ischemic stroke. Mol Neurobiol. doi:10.1007/s12035-014-8725-6
37. Chu J, Li JG, Giannopoulos PF, Blass BE, Childers W, Abou-Gharbia M, Pratico D (2015) Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Abeta and tau neuropathology in the triple-transgenic mice. Mol Psychiatry. doi:10.1038/mp.2014.170
38. Mennes E, Dungan CM, Frendo-Cumbo S, Williamson DL, Wright DC (2013) Aging-associated reductions in lipolytic and mitochondrial proteins in mouse adipose tissue are not rescued by metformin treatment. J Gerontol A: Biol Med Sci. doi:10.1093/gerona/glt156
39. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF (2012) Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-kappaB-dependent pathways. Br J Pharmacol 166(6):1964–1976. doi:10.1111/j.1476-5381.2012.01905.x
40. Renno WM, Al-Banaw AG, George P, Abu-Ghefreh AA, Akhtar S, Benter IF (2012) Angiotensin-(1-7) via the mas receptor alleviates the diabetes-induced decrease in GFAP and GAP-43 immunoreactivity with concomitant reduction in the COX-2 in hippocampal formation: an immunohistochemical study. Cell Mol Neurobiol 32(8):1323–1336. doi:10.1007/s10571-012-9858-7
41. Delobel P, Lavenir I, Fraser G, Ingram E, Holzer M, Ghetti B, Spillantini MG, Crowther RA et al (2008) Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol 172(1):123–131. doi:10.2353/ajpath.2008.070627
42. Jiang T, Gao L, Guo J, Lu J, Wang Y, Zhang Y (2012) Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia. Br J Pharmacol 167(7):1520–1532. doi:10.1111/j.1476-5381.2012.02105.x
43. Lu J, Jiang T, Wu L, Gao L, Wang Y, Zhou F, Zhang S, Zhang Y (2013) The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats. Neuropeptides 47(5):289–295. doi:10.1016/j.npep.2013.09.002
44. Pena Silva RA, Kung DK, Mitchell IJ, Alenina N, Bader M, Santos RA, Faraci FM, Heistad DD et al (2014) Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice. Hypertension. doi:10.1161/HYPERTENSIONAHA.114.03415